Paper Details

  1. Home
  2. Paper Details

Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.

Author: AguiarBruna Forte, BittarCintia, CamposGuilherme Rodrigues Fernandes, MarquesNayara Nathie, MartinelliAna de Lourdes Candolo, MolinaBárbara Floriano, PereiraLeonardo Régis Leira, RahalPaula, RodriguesJoão Paulo Vilela, SouzaFernanda Fernandes

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Direct-acting antivirals (DAAs) are effective for the treatment of chronic hepatitis C, but viral resistance mutations can lead to treatment failure.
Paper Details　
Original Abstract of the Article :
The World Health Organization estimates that 1% of the world population (71 million) is infected with hepatitis C virus (HCV). In 2015, three direct-acting antivirals (DAAs), simeprevir (SMV), sofosbuvir (SOF) and daclatasvir (DCV) were included in the Brazilian protocol for the treatment of chronic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinre.2019.07.015

データ提供：米国国立医学図書館（NLM）

HCV Genotype 1 and Resistance to Treatment: A Challenging Landscape

In the realm of [Hepatitis C treatment], we face the challenge of [viral resistance] to [direct-acting antivirals (DAAs)], such as [simeprevir (SMV), sofosbuvir (SOF), and daclatasvir (DCV)]. This research investigates the presence of [baseline resistance associated substitutions] in [HCV genotype 1] infected patients treated with these DAAs.

This study, conducted in Brazil, analyzed a cohort of patients infected with HCV genotype 1 who were treated with SMV, SOF, and DCV. The researchers investigated the presence of viral resistance mutations and their impact on treatment response.

Understanding the Barriers to Treatment

This research provides valuable insights into the complex landscape of HCV genotype 1 and its potential resistance to DAAs.

Navigating Resistance in Hepatitis C Treatment

This study highlights the importance of understanding the potential for viral resistance in HCV treatment. It reminds us that, like a camel navigating a shifting sandstorm, we must be prepared to adapt our treatment strategies to overcome these challenges.

Dr. Camel's Conclusion

This study explores the challenges posed by baseline resistance associated substitutions in HCV genotype 1, highlighting the importance of monitoring for these mutations and adjusting treatment strategies accordingly.

Date :
  1. Date Completed 2021-09-08
  2. Date Revised 2021-09-08
Further Info :

Pubmed ID

31523019

DOI: Digital Object Identifier

10.1016/j.clinre.2019.07.015

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.